Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$2.79 +1.5%	$2.44	$1.42 ▼ $5.97	$38.42M	1.33	56,941 shs	92,466 shs
ENLV Enlivex Therapeutics	$1.03 -6.4%	$1.26	$0.81 ▼ $2.10	$26.02M	0.8	1.26 million shs	934,986 shs
SNYR Synergy CHC	$2.90 +1.4%	$3.22	$1.19 ▼ $10.00	$26.96M	N/A	51,274 shs	31,014 shs
SONN Sonnet BioTherapeutics	$3.38 +5.0%	$3.58	$1.08 ▼ $19.30	$10.19M	1.04	772,252 shs	299,422 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-1.08%	+16.03%	-21.20%	+63.59%	-28.57%
ENLV Enlivex Therapeutics	+4.76%	-29.49%	-7.56%	+14.33%	-12.70%
SNYR Synergy CHC	-12.80%	-25.91%	-18.29%	+40.20%	+9,433.33%
SONN Sonnet BioTherapeutics	+0.94%	-18.48%	-37.48%	+187.50%	-44.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALC CalciMedica	3.4362 of 5 stars	3.5	5.0	2.6	3.3	0.0
ENLV Enlivex Therapeutics	3.3257 of 5 stars	3.7	5.0	2.9	0.8	0.6
SNYR Synergy CHC	4.349 of 5 stars	3.8	0.0	2.9	3.3	3.1
SONN Sonnet BioTherapeutics	3.1717 of 5 stars	3.5	4.0	1.8	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	3.00	Buy	$16.00	473.48% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	870.87% Upside
SNYR Synergy CHC	3.50	Strong Buy	$10.00	244.83% Upside
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	491.72% Upside

Current Analyst Ratings Breakdown

Latest SONN, CALC, ENLV, and SNYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
SNYR Synergy CHC	$34.83M	0.79	$0.27 per share	10.73	($1.31) per share	-2.21
SONN Sonnet BioTherapeutics	$20K	535.73	N/A	N/A	($0.96) per share	-3.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
SNYR Synergy CHC	$2.12M	$0.38	7.63	4.92	N/A	10.02%	-18.56%	20.28%	N/A
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-4,646.10%	-342.21%	N/A

Latest SONN, CALC, ENLV, and SNYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SNYR Synergy CHC	$0.08	$0.17	+$0.09	$0.17	$10.80 million	$6.74 million
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	-$0.95	-$0.46	-$0.95	N/A	N/A
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
SNYR Synergy CHC	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.39	5.45	5.45
ENLV Enlivex Therapeutics	N/A	7.20	7.20
SNYR Synergy CHC	N/A	2.74	1.62
SONN Sonnet BioTherapeutics	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
ENLV Enlivex Therapeutics	1.02%
SNYR Synergy CHC	N/A
SONN Sonnet BioTherapeutics	9.45%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	41.55%
ENLV Enlivex Therapeutics	12.28%
SNYR Synergy CHC	56.60%
SONN Sonnet BioTherapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
SNYR Synergy CHC	40	9.44 million	4.10 million	N/A
SONN Sonnet BioTherapeutics	10	3.17 million	3.10 million	Not Optionable

SONN, CALC, ENLV, and SNYR Headlines

Recent News About These Companies

Sonnet BioTherapeutics (NASDAQ:SONN) Upgraded at Wall Street Zen

August 19 at 2:27 AM | americanbankingnews.com

Sonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting Standards

August 15, 2025 | msn.com

Sonnet BioTherapeutics (SONN) Expected to Announce Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Sonnet Releases Virtual Investor "What This Means" Segment

August 11, 2025 | globenewswire.com

This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?

August 6, 2025 | msn.com

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

August 4, 2025 | globenewswire.com

Beyond BTC and ETH: The Companies Turning to Alternative Crypto Treasury Assets

August 2, 2025 | msn.com

Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao

August 1, 2025 | tipranks.com

Solana-based treasury model goes global as DeFi Development launches franchise

July 17, 2025 | msn.com

WLFI tokens to become tradable after World Liberty holders’ vote

July 17, 2025 | msn.com

Hyperliquid Strategies Inc. plan for $583M treasury boosts HYPE price

July 16, 2025 | cointelegraph.com

Sonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE Treasury

July 15, 2025 | thecurrencyanalytics.comT

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

July 15, 2025 | msn.com

Public Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New Deal

July 14, 2025 | coinspeaker.com

Sonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.

July 14, 2025 | marketwatch.com

Why did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?

July 14, 2025 | tokenist.comT

Hyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrand

July 14, 2025 | fxstreet.com

HYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid Strategies

July 14, 2025 | msn.com

Massive deal sends biotech stock rallying 367%

July 14, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)

July 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SONN, CALC, ENLV, and SNYR Company Descriptions

CalciMedica NASDAQ:CALC

$2.79 +0.04 (+1.45%)

Closing price 03:59 PM Eastern

Extended Trading

$2.86 +0.06 (+2.33%)

As of 04:42 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Enlivex Therapeutics NASDAQ:ENLV

$1.03 -0.07 (-6.36%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 +0.03 (+2.91%)

As of 07:58 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Synergy CHC NASDAQ:SNYR

$2.90 +0.04 (+1.40%)

As of 03:59 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.

Sonnet BioTherapeutics NASDAQ:SONN

$3.38 +0.16 (+4.97%)

Closing price 04:00 PM Eastern

Extended Trading

$3.33 -0.05 (-1.48%)

As of 07:59 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time